[Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer].
OBJECTIVE
To compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer.


METHODS
A total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed.


RESULTS
The response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% (P = 0.687), and the total response rates were 27.1% and 25.0% (P = 0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9% and 36.6% (P = 0.437), as second-line were 47.8% and 24.2% (P = 0.033), in total treatments were 47.5% and 27.7% (P = 0.001). The median interval to treatment failure (TTF) was 5 months and 2 months (P < 0.001), and that to progression (TTP) was 5 and 2.5 months (P < 0.001) in endocrine therapy and chemotherapy group, respectively.


CONCLUSIONS
Endocrine therapy is superior to chemotherapy for bone metastasis of breast cancer.
Yan
Min
M
Department of Breast Cancer, No.307 Hospital, Academy of Military Medical Sciences, Beijing 100039, China.
Song
San-Tai
ST
Jiang
Ze-Fei
ZF
Zhang
Shao-Hua
SH
Liu
Xiao-Qing
XQ
Xu
Jian-Ming
JM
Wang
Tao
T
Luo
Wei-Dong
WD
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D017211:Treatment Failure
D000970:Antineoplastic Agents